Avsnitt
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Develop a treatment plan for managing patients with AD and/or PN based on current guidelines and evolving clinical data, including specialty referral when appropriateApply communication strategies to facilitate SDM in the management of patients with AD and PN to improve adherence and outcomes
https://www.mycme.com/courses/collaborative-care-in-atopic-dermatitis-and-prurigo-nodularis-9892
Summary
In this concise CME/CE podcast, a dermatologist and primary care clinician review treatment options for patients with atopic dermatitis and prurigo nodularis. Using case examples, the clinicians provide education on individualizing treatment by evaluating patients for treatment progress, modifying treatment plans, and using shared decision-making.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Recognize the similarities and differences in the clinical presentations, symptoms, and triggers of AD and PN, including in patients with skin of colorDescribe the role of type 2 inflammation in the pathophysiology of AD and PN
https://www.mycme.com/courses/recognizing-atopic-dermatitis-and-prurigo-nodularis-9891
Summary
In this concise CME/CE podcast, a dermatologist and a primary care clinician discuss atopic dermatitis and prurigo nodularis—two conditions that often present with relentless itch and can significantly affect patients’ quality of life. Listen as the two clinicians detail the influence of type 2 inflammation and inflammatory cytokines on the pathophysiology of these diseases, as well as describe their clinical manifestations across skin types. By the end of this podcast episode, listeners will feel much more confident in their ability to identify atopic dermatitis and prurigo nodularis in clinical practice.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Saknas det avsnitt?
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. Discussion by:
Guest:
Carol Wysham, M.D,
Clinical Associate Professor of Medicine
University of Washington School of Medicine
Section Head of the Department of Diabetes and Endocrinology
Rockwood Clinic in Spokane, Washington.2. Cervical Cancer: Screening – Draft statement of the U.S. Preventive Services Task Force. Discussion by:
Guest:
Amy Clouse
Associate Clinical Professor
Sidney Kimmell Medical College of Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington3. Chocolate intake and risk of type 2 diabetes: prospective cohort studies. The British Medical Journal 2024. Discussion by:
Guest:
Elyssa Heisey, DO
Resident– Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/adult-adhd-diagnosis-and-management-9854Summary
Adult ADHD is a neurodevelopmental disorder that often persists from childhood into adulthood, affecting attention, impulsivity, and executive function. Despite increased awareness, ADHD in adults remains underdiagnosed and undertreated, presenting unique challenges in clinical practice. This presentation focuses on strategies to address these challenges, drawing insights from recent data and provides our experts recommendations.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss key findings from the CDC report on adult ADHD, including trends in prevalence, diagnostic gaps, and barriers to effective treatment. They also explore the latest research on gender differences in ADHD, emphasizing how these disparities impact diagnosis and treatment approaches. Our experts highlight the need for tailored strategies to ensure more accurate and effective care, especially given that women are often diagnosed later in life and may experience different symptom presentations than men.This podcast was recorded and is being used with permission of the presenters.
Review key insights from the CDC report regarding the prevalence, diagnosis trends, and treatment challenges of ADHD in adultsExamine the latest data on gender differences in ADHD diagnosis and treatment
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially supported.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Describe the correct diagnostic algorithm for suspected ATTR, including interpretation of the monoclonal protein screen and indications for biopsy and genetic testing.Initiate appropriate management, including disease-directed therapy and appropriate cardiac care, or referral when indicated.
https://www.mycme.com/courses/questions-and-answers-on-amyloid-cardiomyopathy-and-polyneuropathy-9845
Summary
In this activity – which learners can review as a podcast or a webcast - Drs. Chafic Karam and Michelle Kittleson dive into five key questions from recent live-virtual broadcasts about transthyretin amyloidosis (ATTR). They discuss the role of cardiac MRI, biopsy, and genetic testing in diagnosing ATTR cardiomyopathy and polyneuropathy. They also explore treatment options, including silencing therapies and stabilizers, with insights into when patients should be referred for specialized care. The conversation emphasizes the importance of early diagnosis, collaborative care between neurologists and cardiologists, and the expanding therapeutic landscape for ATTR.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).
In support of improving patient care, this activity has been planned and implemented by Haymarket Medical Education (HME) and NACE. Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This knowledge-based activity JA4008232-9999-24-043-H01-P qualifies for 0.25 contact hours (0.025 CEUs) of continuing pharmacy education credits.
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc., and an educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/streamlined-strategies-for-managing-tardive-dyskinesia-9842
Summary
Tardive dyskinesia (TD) is a debilitating movement disorder that manifests as involuntary, repetitive movements, often of the face, tongue, and extremities. These symptoms frequently result from prolonged use of antipsychotic medications, particularly in patients being treated for schizophrenia, bipolar disorder, or major depressive disorder. Accurate and routine assessment of TD is critical to prevent symptom progression and improve patient outcomes. The Abnormal Involuntary Movement Scale (AIMS) is a widely accepted, gold-standard tool used to detect and measure the severity of involuntary movements. AIMS enables clinicians to detect involuntary movements early and track the disorder's progression, facilitating timely intervention and individualized treatment plans.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic delve into the complexities of diagnosing and managing tardive dyskinesia (TD), emphasizing evidence-based strategies to improve patient outcomes. They discuss the importance of using the Abnormal Involuntary Movement Scale (AIMS), a standardized and validated tool, for regular TD assessment. AIMS enables clinicians to detect involuntary movements early and track the disorder's progression, facilitating timely intervention and individualized treatment plans.Learning Objective
Explore strategies to simplify management and optimally improve outcomes for patients with TD
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Neurocrine Biosciences.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Discussion by:
Guest:
Muthiah Vaduganathan, MD
Co-Director of the Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital.2. Screen Use at Bedtime and Sleep Duration and Quality Among Youths
– JAMA Pediatrics 2024. Discussion by:
Guest:
Conor Bradley MD
Resident– Family Medicine Residency Program
Jefferson Health – Abington3. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis . New England Journal of Medicine. Discussion by:
Guest:
Michelle Buchbinder, MD
Resident– Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/leaky-gut-leaky-brain-addressing-gut-brain-axis-9815
Summary
Though it is widely acknowledged that the gut is our largest endocrine and immune organ, its role in brain health is less well-known. When is the last time you asked a patient with depression about their diet? Mental health care expands beyond pharmacologic treatment, as explained in this activity detailing the influence of the gut-brain axis on neuroinflammation and the role that diet and pre/probiotics can play in mental health treatment.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the gut-brain axis and its influence on brain health, from its role in the manifestation of certain brain disorders and how we can target the gut to ultimately improve patient outcomes in psychiatry.This podcast was recorded and is being used with permission of the presenters.
Identify the key mechanisms of the gut-brain axis influence on brain disorders.Discuss ways of incorporating understanding of gut dysbiosis into comprehensive treatment of psychiatric disorders.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially funded.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Describe the correct diagnostic algorithm for suspected ATTR, including interpretation of the monoclonal protein screen and indications for biopsy and genetic testingInitiate appropriate management, including disease-directed therapy and appropriate cardiac care, or referral when indicated
https://www.mycme.com/courses/management-of-amyloid-cardiomyopathy-and-polyneuropathy-9813
Summary
In this CME/CE podcast episode, Cardiologist Dr. Michelle Kittleson and Neurologist Dr. Chafic Karam discuss the multidisciplinary management of transthyretin amyloidosis (ATTR). They explore how ATTR affects both the heart and the nervous system, focusing on recognizing symptoms, diagnosing the disease, and managing treatment. Dr. Karam shares insights on peripheral neuropathy caused by amyloidosis, including clues that suggest amyloidosis over more common neuropathies. Dr. Kittleson highlights how cardiologists assess and manage TTR cardiomyopathy, emphasizing the importance of early diagnosis and the evolving therapeutic landscape. Together, they discuss the collaborative nature of care, the impact of new therapies on clinical outcomes, and the importance of raising awareness for ATTR.
Learning ObjectivesThis activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Alnylam Pharmaceuticals Inc., and an educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/vmat2-inhibitors-in-tardive-dyskinesia-9799
Summary
Tardive dyskinesia (TD) is a syndrome characterized by various iatrogenic movement disorders resulting from dopamine receptor antagonism. These movement disorders include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other abnormal involuntary movements, most commonly emerging after prolonged antipsychotic use.Vesicular monoamine transporter type 2 (VMAT2) inhibitors are now available in the United States for managing dyskinesia syndromes, each with a slightly different range of approved indications. VMAT2 inhibitors are agents that cause a depletion of neuroactive peptides such as dopamine in nerve terminals and are used to treat chorea due to neurodegenerative diseases or dyskinesias due to neuroleptic medications (tardive dyskinesia).
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the structural and pharmacokinetic differences between these agents, understanding how they modulate dopamine levels at hypersensitive D2 receptors, common in TD. The program emphasizes the importance of VMAT2 inhibition and its interaction with antipsychotic medications.This podcast was recorded and is being used with permission of the presenters.
Examine the pharmacologic differences between the various VMAT2 inhibitors
Learning Objective
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Neurocrine Biosciences.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Discussion by:
Guest:
Muthiah Vaduganathan, MD
Co-Director of the Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital.2. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening– NEJM 2024. Discussion by:
Guest:
Mathew Clark, MD
Clinical Professor at the Sidney Kimmel medical college of
Thomas Jefferson University
Associate Director Family Medicine Residency Program
Jefferson Health - Abington3. Mindfulness Meditation vs Escitalopram for Treatment of Anxiety Disorders
Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open Discussion by:
Guest:
Kim Alfonzo, MD
Resident– Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/dare-to-move-beyond-symptom-improvement-schizophrenia-9781Summary
Detection – The importance of early detection and intervention in reducing the burden of schizophrenia and increasing recovery chances.Adherence – Shared decision-making for optimal medication choice, focusing on balancing efficacy and minimizing adverse effects that can lead to nonadherence (e.g., sedation, weight gain).Recovery – Functional recovery, quality of life, and achieving personal life goals as key outcomes in treatment.Engagement – Supporting patients in leading purposeful and meaningful lives.
Schizophrenia is a chronic and debilitating mental illness that significantly affects not only the health, well-being, and functioning of patients but also their surrounding environment. Promoting resilience is essential for enhancing health as well as treating mental health issues. A fresh perspective on schizophrenia emphasizes early intervention, symptom enhancement, relapse prevention, functional advancement, and quality of life improvement. The importance of personalized care to improve functional outcomes for individuals living with the condition gain insights into the DARE approach:In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the DARE approach and how shifting the goals of schizophrenia treatment toward not just response and remission but full recovery and resilience, underscore a holistic approach to mental health.
Evaluate the latest advancements in functional domains for schizophrenia treatment.Discuss personalized treatment to improve functional outcomes for individuals living with schizophrenia.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially funded.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA 2024. Discussion by:
Guest:
Stephen Salloway, MD
Director of Neurology and the Memory and Aging Program at Butler Hospital
Professor of Psychiatry and Professor of Neurology at the
Warren Alpert Medical School of Brown University.2. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity - (The SURMOUNT OSA Trial) – NEJM 2024. Discussion by:
Guest:
Atul Malhotra, MD
Professor of Pulmonary Critical Care & Sleep Medicine
Previous at the University of California, San Diego.3. Relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of the evidence. Journal of Infection July 2024. https://doi.org/10.1016/j.jinf.2024.106187 Discussion by:
Guest:
Anupriya Grover-Wenk, MD
Faculty– Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/navigating-the-complexities-of-mixed-mood-states-9705
Summary
Mixed episode bipolar disorders are now referred to as "mixed features" they occur when a person experiences symptoms of depression and mania simultaneously, according to the latest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). This shift reflects a broader understanding of the condition. Understanding and distinguishing these mixed mood states across Bipolar I, Bipolar II, and MDD is crucial for accurate diagnosis and management. Additionally, reviewing existing evidence on the efficacy, tolerability, and safety of treatments tailored to these conditions is essential for optimizing patient outcomes.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic dive into the complexities of mixed mood states in Bipolar I, Bipolar II, and Major Depressive Disorder (MDD). These mixed states involve the simultaneous experience of both manic or hypomanic and depressive symptoms, creating a unique challenge for diagnosis and treatment. This podcast will distinguish these mixed mood states across different disorders and review the latest evidence on the efficacy, tolerability, and safety of treatments designed to manage these challenging conditions.
This podcast/webcast was recorded and is being used with permission of the presenters.Learning Objectives
Distinguish mixed mood states associated with Bipolar I, Bipolar II, and MDDReview existing evidence pertaining to efficacy and tolerability/safety of treatments for Bipolar I, Bipolar II, and MDD with mixed features
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially funded.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/tackling-residual-risk-in-ascvd-and-ckd-9653
Summary
Inflammation plays a pivotal role in both cardiovascular and chronic kidney disease, making it a crucial target for reducing patient risk. In this focused 15-minute podcast, our experts break down the latest insights into how inflammation drives these conditions and explore innovative approaches to managing it.Listen to Dr. Ridker as he will delve into the critical role of inflammation in cardiovascular and chronic kidney disease, with a focus on the predictive value of hsCRP as a biomarker for ASCVD and CKD risk. Dr. Ridker explores emerging strategies to address inflammation, and how these advancements could potentially reduce cardiovascular risk and improve patient outcomes.
Learning Objective
Recognize the role of hsCRP as a biomarker in evaluating the risk of ASCVD and CKDIdentify the role of current and emerging agents, based on their mechanism of action, to target inflammation and potentially reduce cardiovascular risk
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an independent medical educational grant from Novo Nordisk.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Integrate multidisciplinary management for patients with fibrosing ILDs to manage comorbidities and monitor for the need for specialty center referral
https://www.mycme.com/courses/circling-the-wagons-to-care-fibrosing-ilds-9649
Summary
Navigating the challenges of fibrosing ILDs requires a team approach. In this podcast, explore the "Dream Team" of healthcare professionals who collaborate to address the diverse needs of patients with IPF, SSc-ILD, and PPF. From pulmonologists to therapists and beyond, uncover the critical roles each plays in managing comorbidities, symptoms, and overall well-being. Gain valuable insights on when to refer to a specialized ILD center for comprehensive care.
Learning Objective
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
- Visa fler
